Pall Corporation, a global leader in filtration, separation and purification, has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company.
This partnership aligns Pall Biotech equipment and consumables with the Celltheon SMART Expression Platform to deliver integrated manufacturing solutions for customers developing biotherapeutics. Cooperation of Pall Corporation and Celltheon aimed to enable better, safer and faster biologic production.
Based in Union City, California (USA), Celltheon Corporation is focused on cell line and process development for biologics manufacturing. The team offers off-the-shelf, yet customizable solutions for the expression of a wide variety of recombinant proteins via the proprietary Celltheon SMART Expression Platform of technologies and services. Celltheon has developed and integrated consistent and high productivity technologies at every step in the upstream bioproduction process. The Celltheon SMART Expression Platform has been validated on a number of pre-clinical and clinical stage molecules.
Founded in 1946 and headquartered in Port Washington, New York (USA), Pall Corporation is a global supplier of filtration, separations and purification products. Life Sciences segment of Pall Corporation provides technologies that facilitate the process of drug discovery, development, regulatory validation, and production, which are used in the research laboratories, pharmaceutical, biotechnology. It offers medical products to control the spread of infections in hospitals; cell therapy products; and filtration and purification technologies, associated hardware, and engineered systems for the development and commercialization of drugs, plasma, and vaccines. This segment also provides validation services to drug manufacturers; offers laboratory products for use in drug research and discovery, quality control testing, and environmental monitoring applications.